Read your clearance letter first
Your clearance letter and its Indications for Use statement (Form FDA 3881) set the limit for every claim you make. Copy the indications statement word for word into one document; that sentence is what your website, IFU, deck, ads and sales team may promote.
Then look up your record in the FDA 510(k) database by K number. The trade name, product code and indication listed there are what hospital buyers and value analysis committees check against your materials, so your materials must match it. You can also see who else cleared a similar device this year on the list of recent FDA 510(k) clearances.
Promoting a use outside the letter is not a wording problem. FDA treats your advertising and sales statements as evidence of the device's intended use (21 CFR 801.4), and a major change in intended use requires a new 510(k) (21 CFR 807.81(a)(3)). In 2023 FDA sent iRhythm Technologies a warning letter that cited, among other issues, marketing a monitor for "high-risk patients" when its clearance covered non-critical care patients.
What you can say now, and what you cannot
You can say the device is FDA cleared for the indication as written. Any wording that suggests FDA approved, endorsed or certified it is misleading under 21 CFR 807.97.
| Say | Do not say |
|---|---|
| FDA cleared | FDA approved |
| 510(k) cleared | FDA certified |
| Cleared by the FDA for [indication as written in the letter] | FDA endorsed |
| Received 510(k) clearance from the U.S. Food and Drug Administration | "FDA registered" as a claim about the product (21 CFR 807.39) |
| Your K number, if you choose to show it | The FDA logo (FDA name and logo policy) |
| Any indication, patient group or setting not in the letter | |
| Better, safer or faster than a named competitor without head‑to‑head data |
- De Novo: FDA "grants" a De Novo request and the device receives marketing authorization; say "authorized by FDA through the De Novo pathway" or "granted De Novo." "FDA cleared" is wrong, because there was no 510(k) clearance.
- PMA: "FDA approved" is correct only for a device approved through premarket approval.
For the full wording guide, read FDA cleared vs FDA approved. For claims beyond regulatory status (clinical data, comparisons, testimonials), read 510(k) marketing claims. For other pathways, read De Novo and PMA wording.
Announcing the clearance
Announce once you hold the signed substantial equivalence (SE) letter. Until then the device may not be marketed (21 CFR 807.100(a); FDA, Premarket Notification 510(k)). FDA sets no other rule on when you announce, and you do not need to wait for the clearance to appear in the FDA database.
The release must include:
- "510(k) clearance" in the headline
- The cleared indication, quoted from the letter
- A quote from a named company spokesperson
- No predictions of patient outcomes
The release must not include:
- "Approved," in any form
- "Best," "leading" or "first," unless you can prove it
- Clinical claims beyond the letter
Post it on your own newsroom page first, so the wire story and press coverage link back to you. Then send it on the wire, pitch it to trade press for your specialty, and have the founders post it on LinkedIn in their own words, using the same cleared wording.
If your company is publicly traded, your securities disclosure rules decide when and how the news is released. Read medical device press releases that get picked up for headline and distribution detail.
Make the website, IFU and label say the same thing
Your website, IFU, label, sales deck and booth graphics must describe one device with one indication. If they differ, a buyer or an FDA reviewer will notice the version that goes furthest.
- Remove "pending FDA clearance," "investigational" and "not available for sale in the US" only from the configuration that was cleared. Keep it on any model, accessory or use that is still under review. Any device still in a clinical study under an IDE must keep the investigational caution label (21 CFR 812.5) and may not be promoted (21 CFR 812.7).
- On each product page, state the cleared indication word for word.
- Build a claims bank: one document of 30 to 50 approved sentences plus your safety statement, signed by your regulatory lead. Your agency, sales team and founders write from that document and nothing else. A new claim is added only after the same sign-off.
- Train your sales reps on the claims bank before their first call. What a rep says to a surgeon is your company's promotion, the same as an ad.
- Clinicians you pay to post or speak about the device are also your promotion: they use the claims bank and disclose that you pay them (16 CFR Part 255).
- If reimbursement for your device is not settled, say so. Do not imply insurance coverage you have not confirmed.
Read labeling and IFU requirements for what the label and IFU must contain.
Sales materials buyers ask for
What you build depends on how your device is sold. Most companies have one main route for the first 90 days.
- Online store (one clinician buys by card): product pages with price and specifications, and a product feed for Google Shopping.
- Consultation and sample (a practice buys after a demo or sample): one request page per product, with a promise in writing that someone calls within 5 business days.
- Rep and distributor (a hospital buys through a value analysis committee):
- Surgical technique guide
- Surgeon video
- A one-page value dossier for the committee: clearance, indications, evidence, price position, reimbursement, and the sets and training plan
- A distributor kit: deck, dossier, technique guide and case videos
- Patient facing (the patient asks a physician): a patient page and a separate physician page. Patients and physicians need different words and different next steps.
The 30/60/90 plan
The plan below assumes the claims bank comes first, because every page, ad and email after it draws from that document.
| Days | What gets done |
|---|---|
| 1 to 30 | Claims bank signed. You own every ad, analytics and LinkedIn account in your company's name. Tracking proven on one real request or order. One conversion page per product. The clearance announcement. |
| 31 to 60 | Brand search ads so your company name is not bought by a competitor. One paid channel aimed at the people who buy; LinkedIn for clinicians and committee members. A before and after campaign for your next conference. Follow‑up email to everyone who asked. |
| 61 to 90 | Results read at day 45 and day 90 from your own CRM or store records, not the ad platform's numbers. Each channel is kept, changed or stopped. |
If you have not cleared yet, start with the 90 days before clearance.
What it costs
Most work starts with a 90-day plan and test, from $5,000. Ongoing programs start at $2,500 a month. The 90-day plan and test covers the plan, the first work in market and written reports at day 45 and day 90. Ad spend is paid on your own card, directly to Google, LinkedIn or the other platforms, and is not part of these fees.
Where you land depends on how many channels you run, how many products you launch and how much claim review your regulatory team needs.
Hiring an agency after clearance: four questions
Ask each agency these four questions before you sign:
- Will you check every claim against our clearance letter? Ask to see how they do it.
- Will we own every account and all the data? Ad, analytics and LinkedIn accounts should be in your company's name, with the agency added as a user.
- How will results be judged? The answer should be your CRM or store records, not the ad platform's own reports.
- Who does the work? Ask for the names of the people who will write and run it.
Buzzbox Media built the brand identity, website and trade show presence for the launch of True Digital Surgery, a B. Braun company, and its surgical visualization platform (case study).
To talk through your launch, book a free 30-minute call with Baron Miller. See Buzzbox Media's medical device branding and medical device marketing services.
